Amy Otto is Senior Vice President, Program Leadership at Marengo Therapeutics, where she leads integrated development strategy and cross-functional execution for invikafusp alfa, partnering with Marengo’s leadership and functional teams to advance the program’s clinical, regulatory and operational priorities.

Amy brings more than 20 years of oncology development leadership across Amgen, Seagen and Gilead, with experience spanning early development through regulatory approval, global launch and lifecycle expansion. Most recently, she served as Vice President and Head of Oncology Program Strategy Leadership at Gilead, where she grew the oncology program strategy function and shaped portfolio and program decisions across the pipeline of oncology investigational assets, including TRODELVY®. Previously, she was Product Team Leader for PADCEV® at Seagen, leading the program through late-stage development, FDA approval, global launch and lifecycle expansion.

Amy holds an MBA from Pepperdine University and a B.S. in Biochemistry from the University of Delaware.